Key result
Pantera Lux paclitaxel-coated balloon shows a ~15% 12-month MACE rate in a real-world registry.
Why the study?
Safety and efficacy of the Pantera Lux paclitaxel-coated balloon were previously demonstrated in a first-in-man trial, but data in a larger international real-world cohort were needed.
Observational (n=1,064)
Yes
The use of a paclitaxel-coated balloon demonstrated acceptable safety and efficacy with low MACE rates at 12 months for treating in-stent restenosis and de novo coronary lesions in a real-world registry.
Supports Pantera Lux DCB safety in real-world ISR and de novo lesions; extends PEPPER findings to larger cohort but leaves practice change open.
AIMS: Safety and efficacy of percutaneous coronary interventions using the Pantera Lux paclitaxel-coated balloon have been demonstrated in the PEPPER first-in-man trial. This prospective, multicentre, clinical registry aims to evaluate its safety and efficacy in an international real-world setting in a larger cohort of patients. METHODS AND RESULTS: Between April 2010 and April 2011, 1,064 patients were treated for predominantly diffuse and proliferative in-stent restenosis of bare metal stents (BMS-ISR) and drug-eluting stents (DES-ISR), or for de novo lesions. Clinical device success was obtained in 98.2% of the patients. The study endpoint was major adverse cardiac events (MACE), defined as a composite of all-cause mortality, non-fatal myocardial infarction and clinically driven target vessel revascularisation, and was 8.5% in the overall, 6.0% in the BMS-ISR, 11.5% in the DES-ISR and 7.0% in the de novo population at six months, and 15.1%, 11.6%, 20.6% and 9.4% at 12 months, respectively. Definitive stent thrombosis occurred in 0.4% of the patients within 12 months. CONCLUSIONS: Safety and efficacy of the Pantera Lux paclitaxel-coated balloon was confirmed in a real-world setting with low major adverse cardiac event rates in patients with in-stent restenosis or de novo lesions. (ClinicalTrials.gov: NCT01081366).
No takes yet. Share an insight, caveat, or question.
Töelg et al. (2014) conducted an observational in In-stent restenosis or de novo coronary lesions (n=1,064). Pantera Lux paclitaxel-coated balloon was evaluated on Major adverse cardiac events (MACE), defined as a composite of all-cause mortality, non-fatal myocardial infarction and clinically driven target vessel revascularisation at 12 months. In a real-world registry, treatment with the Pantera Lux paclitaxel-coated balloon resulted in an overall 12-month major adverse cardiac event rate of 15.1%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: